[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY38006A - Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones - Google Patents

Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones

Info

Publication number
UY38006A
UY38006A UY0001038006A UY38006A UY38006A UY 38006 A UY38006 A UY 38006A UY 0001038006 A UY0001038006 A UY 0001038006A UY 38006 A UY38006 A UY 38006A UY 38006 A UY38006 A UY 38006A
Authority
UY
Uruguay
Prior art keywords
therapy
compounds
mtor
kinasa
inhibitors
Prior art date
Application number
UY0001038006A
Other languages
English (en)
Inventor
Gianpaolo Bravi
Heather Hobbs
Graham George Adam Inglis
Simon Nicolle
Simon Peace
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of UY38006A publication Critical patent/UY38006A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a compuestos de fórmula (I): en donde R1, R2, R3, R4, L y A se definen en la descripción y las reivindicaciones, o las sales farmacéuticamente aceptables de los mismos que tienen actividad inhibidora de la quinasa mTOR. La invención también se refiere a composiciones farmacéuticas que incluyen un compuesto de fórmula (I) o una sal farmacéuticamente aceptable del mismo, y al uso de un compuesto de fórmula (I) o una sal farmacéuticamente aceptable del mismo en terapia.
UY0001038006A 2017-12-15 2018-12-13 Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones UY38006A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1720989.1A GB201720989D0 (en) 2017-12-15 2017-12-15 Chemical compounds

Publications (1)

Publication Number Publication Date
UY38006A true UY38006A (es) 2019-07-31

Family

ID=61008661

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038006A UY38006A (es) 2017-12-15 2018-12-13 Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones

Country Status (11)

Country Link
US (1) US11254671B2 (es)
EP (1) EP3724187A1 (es)
JP (1) JP2021506809A (es)
CN (1) CN111491932A (es)
AR (1) AR113935A1 (es)
BR (1) BR112020011988A2 (es)
CA (1) CA3085666A1 (es)
GB (1) GB201720989D0 (es)
TW (1) TW201938161A (es)
UY (1) UY38006A (es)
WO (1) WO2019115640A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243446A1 (en) * 2019-05-30 2020-12-03 Children's Hospital Medical Center Methods and compositions for treatment of smith kingsmore syndrome
GB201908536D0 (en) * 2019-06-13 2019-07-31 Glaxosmithkline Ip Dev Ltd Compounds
WO2022175425A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Intellectual Property Development Limited Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
PT77471B (en) 1982-10-08 1986-08-19 Glaxo Group Ltd Devices for administering medicaments to patients
DE3682457D1 (de) 1985-07-30 1991-12-19 Glaxo Group Ltd Geraet zur verabreichung von medikamenten an patienten.
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
SK280968B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Balenie medikamentu na použite v inhalačnom prístroji
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
EP2336185A1 (en) 2002-03-13 2011-06-22 Biogen Idec Inc. Anti- alpha v beta 6 antibodies
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
BRPI0507714B8 (pt) 2004-02-16 2021-07-27 Glaxo Group Ltd contador de dose para uso com um dispensador de medicamento, e, dispensador de medicamento
GB0418278D0 (en) 2004-08-16 2004-09-15 Glaxo Group Ltd Medicament dispenser
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
JP2009523161A (ja) * 2006-01-11 2009-06-18 アストラゼネカ アクチボラグ モルホリノピリミジン誘導体と療法におけるその使用
RU2445312C2 (ru) * 2006-08-23 2012-03-20 Кудос Фармасьютиклз Лимитед ПРОИЗВОДНЫЕ 2-МЕТИЛМОРФОЛИН ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR
JP2010533161A (ja) * 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物−９４６
SA111320519B1 (ar) * 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
CN103402517A (zh) * 2010-11-19 2013-11-20 葛兰素史密斯克莱知识产权（第2号）有限公司 使用braf抑制剂的治疗方法
CN103450204B (zh) * 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
GB201908536D0 (en) * 2019-06-13 2019-07-31 Glaxosmithkline Ip Dev Ltd Compounds

Also Published As

Publication number Publication date
US20210163472A1 (en) 2021-06-03
EP3724187A1 (en) 2020-10-21
CA3085666A1 (en) 2019-06-20
GB201720989D0 (en) 2018-01-31
US11254671B2 (en) 2022-02-22
BR112020011988A2 (pt) 2020-11-17
TW201938161A (zh) 2019-10-01
WO2019115640A1 (en) 2019-06-20
CN111491932A (zh) 2020-08-04
AR113935A1 (es) 2020-07-01
JP2021506809A (ja) 2021-02-22

Similar Documents

Publication Publication Date Title
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CL2018002410A1 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
CL2018003291A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA202090530A1 (ru) Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич
BR112016016844A2 (pt) Compostos heterocíclicos
CU20160109A7 (es) Compuestos de indazol como inhibidores de irak4
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201991884A2 (ru) Ингибиторы g12c kras
CL2019003669A1 (es) Inhibidores de quinasa alk2 que contienen imidazol.
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201690752A1 (ru) Ингибиторы g12c kras
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201791955A1 (ru) ИНГИБИТОРЫ TGF-β
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
UY37160A (es) COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6
EA201692267A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
SV2016005313A (es) Derivados de carboxamida
EA201890532A1 (ru) Новые аннелированные бензамиды